Here is some other vaccine news of note for the week:
> Moderna’s mRNA-1653, a combo vaccine designed to protect against human metapneumovirus and parainfluenza type 3, boosted serum neutralization titers against the two viruses, according to the company’s interim phase 1 data report. Release
> Seqirus’ revenue for the six months ended Dec. 31 grew 21% at constant currency to reach $949 million, driven largely by its flu vaccines, parent company CSL said in a half-year report. Report
> Vaxart plans to start phase 1 bivalent and phase 2 monovalent challenge studies for its oral norovirus vaccine in the first half of 2019, CEO Wouter Latour, M.D., said as the company reported fourth-quarter financial results. Release
> Health experts are calling on Facebook to stem the rise of anti-vaccination groups in which members post misinformation in a closed circle. The Guardian article